title: Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
authors.forename: Ruben A
authors.initials: RA
authors.lastname: Mesa
authors.forename: David P
authors.initials: DP
authors.lastname: Steensma
authors.forename: James
authors.initials: J
authors.lastname: Hoyer
authors.forename: Rhett P
authors.initials: RP
authors.lastname: Ketterling
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D017809:Fatal Outcome; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate